32811-76-0

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 3-Hydroxycyclopentanecarboxylate is utilized as an intermediate in the synthesis of various drugs and active pharmaceutical ingredients. Its role in drug development is pivotal, as it contributes to the creation of new medications that address a spectrum of health conditions.
Used in Agrochemical Industry:
In the agrochemical sector, Methyl 3-Hydroxycyclopentanecarboxylate serves as a key intermediate in the production of compounds that are integral to agricultural applications. Its presence in this industry underscores its importance in developing solutions that enhance crop protection and productivity.
Used in Chemical Industry:
Methyl 3-Hydroxycyclopentanecarboxylate's applications extend to the broader chemical industry, where it is employed in the synthesis of a variety of organic compounds. Its versatility and chemical properties make it a valuable component in numerous chemical processes and end products.

Upstream product

• 32811-75-9 methyl 3-oxocyclopentane-1-carboxylate 
• 98-78-2 3-Oxo-cyclopentanecarboxylic acid 
• 58101-60-3 methyl cyclopent-3-ene-1-carboxylate 

Downstream Products

• 1246212-28-1 methyl 3-(5-bromopyridin-2-yloxy)cyclopentane carboxylate 
• 109646-10-8 (+/-)-cis-3-methoxy-cyclopentanecarboxylic acid p-toluidide 
• 109507-57-5 (+/-)-cis-3-hydroxy-cyclopentanecarboxylic acid p-toluidide 
• 5732-97-8 2-oxa-bicyclo[2.2.1]heptan-3-one 
• 55843-47-5 (+/-)-cis-3-hydroxy-cyclopentanecarboxylic acid 

Relevant academic research and scientific papers

INHIBITORS OF RHO/MRTF/SRF-MEDIATED GENE TRANSCRIPTION AND METHODS FOR USE OF THE SAME

Disclosed herein are inhibitors of Rho/MRTF/SRF-mediated gene transcription, and methods for their use in treating or preventing diseases such as cancer and fibrosis. In particular, disclosed herein are compounds of Formula (I) and pharmaceutically accept

N-substituted imidazole carboxylate compounds, and preparation method and medical application thereof

The invention relates to a compound represented as a general formula (I) or a stereoisomer, solvate, pharmaceutically acceptable salt or eutectic crystal of the compound, and a composition, preparation method and medical application of the compound, the stereoisomer, the solvate, the pharmaceutically acceptable salt and the eutectic crystal. The general formula (I) is shown as follows, and the definition of each substituent group is consistent as in the specification.

COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS

Compounds, pharmaceutical compositions, methods and kits are described for treating or preventing neurodegenerative diseases such as Alzheimer's disease.

IRAK4 INHIBITING AGENTS

Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production. Formula (I) The compounds are IRAK-4 inhibitors useful for treating an inflammatory disease, an autoimmune disease, cancer, a cardiovascular disease, a disease of the central nervous system, a disease of the skin, an ophthalmic disease and condition, and a bone disease.

Glutaminase inhibitors as well as compositions and applications thereof

The invention provides a series of heterocyclic compounds expressed in a formula I. The compound comprises glutaminase inhibition activity, and can be used for treating diseases and symptoms related to dysfunction of glutaminase or raising activity of glutaminase.

NOVEL CYCLOPENTANE DERIVATIVES

The invention relates to a compound of formula (I) wherein A1 and R1 to R5 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.

BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE

The present invention relates to novel heterocyclic compounds as diacylglycerol acyltransferase ("DGAT") inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular

Antibacterial agents, and 4-thio azetidinone intermediates

This invention relates to 2-substituted and 2,6-disubstituted penem compounds of the formula STR1 wherein Y is hydrogen, halo or certain organic substituents and X represents certain organic substituents. Also included in the invention are pharmaceutically acceptable salts of the above compounds and derivatives of the above compounds in which the carboxyl group at the 3-position is protected as by an easily removable ester protecting group. The compounds of the present invention are potent antibacterial agents or are of use as intermediates in the preparation of such agents.

Geminal prostaglandin analogs

Geminal prostaglandins (P.G.'s) are synthesized which are represented by the general formula: STR1 where A is a 4 or 5 carbon atom ring-completing group (CH2)1+m --X--(CH2)z where m = 0, 1 or 2, Z = 0 or 1, 02 --CH2 --, --CH2 --CHOH--, STR2 and, when m = 0 and z = 1, is also --CH=CH-- or STR3 Y is divalent straight chain alkylene of 4 to 8 carbon atoms or r is alkyl of 4 to 7 carbon atoms; Q is --CO2 H or --CH2 OH provided that it is not --CH2 OH when X = STR4 or Y--Q taken together may be heptyl or allyl.